Showing results (171-180 of 207) with videos related to

Sort By:
Pageof 21
British Journal of Clinical Pharmacology|May 17, 2020
Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patientsRob Ter Heine, Ron J Keizer, Krista van Steeg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancerE W Steyerberg, A Gerl, S D Fossá, et al.
European Journal of Gastroenterology & Hepatology|October 19, 1999
Treatment of mesenteric desmoid tumours with the anti-oestrogenic agent toremifene: case histories and an overview of the literatureP J Bus, H W Verspaget, J H van Krieken, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 24, 2010
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080Ron J Keizer, Anubha Gupta, Melvin R Mac Gillavry, et al.
Antimicrobial Agents and Chemotherapy|June 4, 2008
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patientsThomas P C Dorlo, Pieter P A M van Thiel, Alwin D R Huitema, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2000
A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remissionS Rodenhuis, R de Wit, P H de Mulder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groupsE W Steyerberg, H J Keizer, S D Fosså, et al.
Anti-Cancer Drugs|March 24, 1998
Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patientsP Boffetta, A M Fichtinger-Schepman, E Weiderpass, et al.
Pageof 21